NICE Reject Eribulin For Breast Cancer Patients
Baroness Delyth Morgan, Chief Executive of Breast Cancer Campaign, responds to NICE’s decision to reject eribulin for the treatment of advanced breast cancer.
“NICE’s decision to reject eribulin to treat advanced breast cancer that has progressed after at least two chemotherapy treatments, further limits the few options available for patients with secondary breast cancer and follows the decision by NICE last week to also reject the use of fulvestrant for the same group of patients.
“NICE has concluded that the clinical trial evidence in support of eribulin is not strong enough to recommend it. We would therefore welcome further evidence on the effectiveness of this treatment, particularly in relation to its potential impact on patients’ quality of life. In the meantime, we would urge all Strategic Health Authorities to ensure that eribulin is available through the Cancer Drugs Fund, if a clinician decides it is a suitable treatment option.
“Breast Cancer Campaign continues to fund research into developing innovative treatments for secondary breast cancer, which will hopefully lead to greater options for patients in the future.”